{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:47:00Z","timestamp":1790444820094,"version":"4.1.0"},"reference-count":128,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:p>Dry eye disease (DED) is a complex disorder of the ocular surface with a loss of tear film homeostasis, causing an imbalance in the tear\u2013air interface and leading to ocular discomfort, pain, and vision issues. Immune control issues are a primary factor in dry eye disorder\u2019s origin, progression, and management. The aim of managing DED is to reduce symptoms and improve the life quality of those affected. Despite the diagnosis, up to half of the patients do not get proper care. The scarcity of successful treatments for DED is worrisome, and it is of increasing importance to comprehend the root causes and create more effective therapies to alleviate the distress of those afflicted with the disorder. Therefore, the role of the immune system in the initiation and progression of DED has become the research focus. This paper reviews the current insight into the immune response in DED, the existing treatment methods, and ongoing research to search for better treatments.<\/jats:p>","DOI":"10.4103\/ijo.ijo_481_23","type":"journal-article","created":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T11:10:52Z","timestamp":1680952252000},"page":"1248-1255","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Intricate insights into immune response in dry eye disease"],"prefix":"10.4103","volume":"71","author":[{"given":"Ruminder P","family":"Kaur","sequence":"first","affiliation":[{"name":"Department of Emergency Medicine, Civil Hospital, Moga, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Gurnani","sequence":"additional","affiliation":[{"name":"Cornea and Refractive Services, Sadguru Netra Chikitsalya, Shri Sadguru Seva Sangh Trust, Janaki-Kund, Chitrakoot, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirandeep","family":"Kaur","sequence":"additional","affiliation":[{"name":"Pediatric Ophthalmology and Strabismus, Sadguru Netra Chikitsalya, Shri Sadguru Seva Sangh Trust, Janaki-Kund, Chitrakoot, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"R1-20240828","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II Epidemiology Report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul Surf"},{"key":"R2-20240828","doi-asserted-by":"crossref","first-page":"108295","DOI":"10.1016\/j.exer.2020.108295","article-title":"The cornea in keratoconjunctivitis sicca","volume":"201","author":"Pflugfelder","year":"2020","journal-title":"Exp Eye Res"},{"key":"R3-20240828","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2147\/OPTH.S281666","article-title":"Trends in dry eye disease management worldwide","volume":"15","author":"Hantera","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"R4-20240828","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.preteyeres.2012.10.002","article-title":"Immunological homeostasis of the eye","volume":"33","author":"Mochizuki","year":"2013","journal-title":"Prog Retin Eye Res"},{"key":"R5-20240828","doi-asserted-by":"crossref","first-page":"9271","DOI":"10.3390\/ijms21239271","article-title":"Defining dry eye from a clinical perspective","volume":"21","author":"Tsubota","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R6-20240828","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/archophthalmol.2011.364","article-title":"Dry eye disease:An immune-mediated ocular surface disorder","volume":"130","author":"Stevenson","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"R7-20240828","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1167\/iovs.11-9299","article-title":"Autoantibodies contribute to the immunopathogenesis of experimental dry eye disease","volume":"53","author":"Stern","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R8-20240828","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.exer.2016.07.004","article-title":"Mucosal tolerance disruption favors disease progression in an extraorbital lacrimal gland excision model of murine dry eye","volume":"151","author":"Guzm\u00e1n","year":"2016","journal-title":"Exp Eye Res"},{"issue":"(11S)","key":"R9-20240828","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.ophtha.2017.07.010","article-title":"The pathophysiology of dry eye disease:What we know and future directions for research","volume":"124","author":"Pflugfelder","year":"2017","journal-title":"Ophthalmology"},{"key":"R10-20240828","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3390\/ijms18050978","article-title":"Goblet cells contribute to ocular surface immune tolerance-implications for dry eye disease","volume":"18","author":"Barbosa","year":"2017","journal-title":"Int J Mol Sci"},{"key":"R11-20240828","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3390\/ijms19020485","article-title":"Integrins in T cell physiology","volume":"19","author":"Bertoni","year":"2018","journal-title":"Int J Mol Sci"},{"key":"R12-20240828","doi-asserted-by":"crossref","first-page":"DES192","DOI":"10.1167\/iovs.17-23651","article-title":"Inflammatory response in dry eye","volume":"59","author":"Yamaguchi","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R13-20240828","doi-asserted-by":"crossref","first-page":"e36822","DOI":"10.1371\/journal.pone.0036822","article-title":"NK cells promote Th-17 mediated corneal barrier disruption in dry eye","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"key":"R14-20240828","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.4049\/jimmunol.1401821","article-title":"Coordinated regulation of NK receptor expression in the maturing human immune system","volume":"193","author":"Strauss-Albee","year":"2014","journal-title":"J Immunol"},{"key":"R15-20240828","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1189\/jlb.1110611","article-title":"Interferon-\u03b3-secreting NK cells promote induction of dry eye disease","volume":"89","author":"Chen","year":"2011","journal-title":"J Leukoc Biol"},{"key":"R16-20240828","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1002\/art.23073","article-title":"Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sj\u00f6gren's syndrome:Correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development","volume":"56","author":"Manoussakis","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R17-20240828","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00005-015-0335-0","article-title":"Macrophage phenotype in the ocular surface of experimental murine dry eye disease","volume":"63","author":"You","year":"2015","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"R18-20240828","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/imm.12716","article-title":"Mucosal immune tolerance at the ocular surface in health and disease","volume":"150","author":"Galletti","year":"2017","journal-title":"Immunology"},{"key":"R19-20240828","doi-asserted-by":"crossref","first-page":"701415","DOI":"10.3389\/fimmu.2021.701415","article-title":"Desiccation induced conjunctival monocyte recruitment and activation-Implications for keratoconjunctivitis","volume":"12","author":"Alam","year":"2021","journal-title":"Front Immunol"},{"key":"R20-20240828","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1167\/iovs.09-3425","article-title":"Expression of CXCL9, -10, -11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome","volume":"51","author":"Yoon","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R21-20240828","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.ajo.2011.08.023","article-title":"Tear dysfunction and the cornea:LXVIII Edward Jackson memorial lecture","volume":"152","author":"Pflugfelder","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"R22-20240828","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ni0407-345","article-title":"T[H]-17 cells in the circle of immunity and autoimmunity","volume":"8","author":"Bettelli","year":"2007","journal-title":"Nat Immunol"},{"key":"R23-20240828","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/mi.2009.5","article-title":"IL-17 disrupts corneal barrier following desiccating stress","volume":"2","author":"De Paiva","year":"2009","journal-title":"Mucosal Immunol"},{"key":"R24-20240828","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.exer.2010.07.008","article-title":"Immune response in the conjunctival epithelium of patients with dry eye","volume":"91","author":"Barabino","year":"2010","journal-title":"Exp Eye Res"},{"key":"R25-20240828","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ajpath.2013.11.019","article-title":"Ocular surface disease and dacryoadenitis in aging C57BL\/6 mice","volume":"184","author":"McClellan","year":"2014","journal-title":"Am J Pathol"},{"key":"R26-20240828","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.4049\/jimmunol.1502641","article-title":"IL-17 Augments B cell activation in ocular surface autoimmunity","volume":"197","author":"Subbarayal","year":"2016","journal-title":"J Immunol"},{"key":"R27-20240828","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/09273948.2021.1980808","article-title":"Pathophysiology of corneal endothelial cell loss in dry eye disease and other inflammatory ocular disorders","volume":"31","author":"Sekhon","year":"2023","journal-title":"Ocul Immunol Inflamm"},{"key":"R28-20240828","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1167\/iovs.61.12.9","article-title":"Lactoferrin concentration in human tears and ocular diseases:A meta-analysis","volume":"61","author":"Ponzini","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R29-20240828","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.3390\/nu13082492","article-title":"Lactoferrin and its detection methods:A review","volume":"13","author":"Zhang","year":"2021","journal-title":"Nutrients"},{"key":"R30-20240828","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jfo.2018.11.001","article-title":"Osmokinetics:A new dynamic concept in dry eye disease","volume":"42","author":"van Setten","year":"2019","journal-title":"J Fr Ophtalmol"},{"key":"R31-20240828","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1167\/iovs.05-1504","article-title":"Tear film osmolarity:Determination of a referent for dry eye diagnosis","volume":"47","author":"Tomlinson","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R32-20240828","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1167\/iovs.09-4596","article-title":"Tear osmolarity as a biomarker for dry eye disease severity","volume":"51","author":"Suzuki","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R33-20240828","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1167\/iovs.11-7627","article-title":"Correlation of tear inflammatory cytokines and matrix metalloproteinases with four dry eye diagnostic tests","volume":"53","author":"VanDerMeid","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R34-20240828","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1167\/iovs.03-1145","article-title":"Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface","volume":"45","author":"Luo","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R35-20240828","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.exer.2005.08.019","article-title":"JNK and ERK MAP kinases mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cells","volume":"82","author":"Li","year":"2006","journal-title":"Exp Eye Res"},{"key":"R36-20240828","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.3390\/ijms22063090","article-title":"Role of the innate immunity signaling pathway in the pathogenesis of Sj\u00f6gren's syndrome","volume":"22","author":"Shimizu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R37-20240828","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1167\/iovs.09-3425","article-title":"Expression of CCL3 and CCL4 in the tear film and ocular surface of patients with dry eye syndrome","volume":"51","author":"Yoon","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R38-20240828","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/02713683.2011.622852","article-title":"Expression of CCR5 and its ligands CCL3, -4, and -5 in the tear film and ocular surface of patients with dry eye disease","volume":"37","author":"Choi","year":"2012","journal-title":"Curr Eye Res"},{"key":"R39-20240828","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.exer.2003.10.024","article-title":"ICAM-1 expression predisposes ocular tissues to immune-based Inflammation in dry eye patients and Sj\u00f6grens syndrome-like MRL\/lpr mice","volume":"78","author":"Gao","year":"2004","journal-title":"Exp Eye Res"},{"key":"R40-20240828","doi-asserted-by":"crossref","first-page":"8410","DOI":"10.3390\/ijms22168410","article-title":"Integrin \u03b1v and vitronectin prime macrophage-related inflammation and contribute the development of dry eye disease","volume":"22","author":"Ho","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R41-20240828","doi-asserted-by":"crossref","first-page":"7514","DOI":"10.3390\/ijms21207514","article-title":"Disease-specific expression of conjunctiva associated lymphoid tissue [CALT] in mouse models of dry eye disease and ocular allergy","volume":"21","author":"Steven","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R42-20240828","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jtos.2017.03.006","article-title":"TFOS DEWS II tear film report","volume":"15","author":"Willcox","year":"2017","journal-title":"Ocul Surf"},{"key":"R43-20240828","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3390\/ijms18061209","article-title":"Pathological analysis of ocular lesions in a murine model of Sj\u00f6gren's syndrome","volume":"18","author":"Ushio","year":"2017","journal-title":"Int J Mol Sci"},{"key":"R44-20240828","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.exer.2013.08.013","article-title":"T helper cytokines in dry eye disease","volume":"117","author":"Pflugfelder","year":"2013","journal-title":"Exp Eye Res"},{"key":"R45-20240828","doi-asserted-by":"crossref","first-page":"102933","DOI":"10.1016\/j.autrev.2021.102933","article-title":"Autoimmunity in dry eye disease-An updated review of evidence on effector and memory Th17 cells in disease pathogenicity","volume":"20","author":"Chen","year":"2021","journal-title":"Autoimmun Rev"},{"key":"R46-20240828","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","article-title":"TFOS DEWS II pathophysiology report","volume":"15","author":"Bron","year":"2017","journal-title":"Ocul Surf"},{"key":"R47-20240828","doi-asserted-by":"crossref","first-page":"2532314","DOI":"10.1155\/2018\/2532314","article-title":"Innate and adaptive cell populations driving inflammation in dry eye disease","volume":"2018","author":"Reyes","year":"2018","journal-title":"Mediators Inflamm"},{"key":"R48-20240828","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.ajpath.2013.12.033","article-title":"How endothelial cells regulate transmigration of leukocytes in the inflammatory response","volume":"184","author":"Muller","year":"2014","journal-title":"Am J Pathol"},{"key":"R49-20240828","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1002\/eji.201040523","article-title":"Dendritic cells adhere to and transmigrate across lymphatic endothelium in response to IFN-\u03b1","volume":"40","author":"Rouzaut","year":"2010","journal-title":"Eur J Immunol"},{"key":"R50-20240828","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3389\/fimmu.2019.00471","article-title":"Leucocyte trafficking via the lymphatic vasculature- Mechanisms and consequences","volume":"10","author":"Jackson","year":"2019","journal-title":"Front Immunol"},{"key":"R51-20240828","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/jop.2019.0060","article-title":"The immunological basis of dry eye disease and current topical treatment options","volume":"36","author":"Periman","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"key":"R52-20240828","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.celrep.2016.12.078","article-title":"T cell migration from inflamed skin to draining lymph nodes requires intralymphatic crawling supported by ICAM-1\/LFA-1 interactions","volume":"18","author":"Teijeira","year":"2017","journal-title":"Cell Rep"},{"key":"R53-20240828","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3390\/ijms22020658","article-title":"The involvement of innate and adaptive immunity in the initiation and perpetuation of Sj\u00f6gren's syndrome","volume":"22","author":"Chivasso","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R54-20240828","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1167\/iovs.08-2417","article-title":"Characterization of effector T cells in dry eye disease","volume":"50","author":"El Annan","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R55-20240828","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.3390\/biom10111539","article-title":"T cells subsets in the immunopathology and treatment of Sjogren's syndrome","volume":"10","author":"R\u00edos-R\u00edos","year":"2020","journal-title":"Biomolecules"},{"key":"R56-20240828","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.exer.2013.11.011","article-title":"Topical interferon-gamma neutralization prevents conjunctival goblet cell loss in experimental murine dry eye","volume":"118","author":"Zhang","year":"2014","journal-title":"Exp Eye Res"},{"key":"R57-20240828","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jtos.2019.12.006","article-title":"Immune-Goblet cell interaction in the conjunctiva","volume":"18","author":"Alam","year":"2020","journal-title":"Ocul Surf"},{"key":"R58-20240828","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/mi.2009.21","article-title":"Role of Th17 cells in the immunopathogenesis of dry eye disease","volume":"2","author":"Chauhan","year":"2009","journal-title":"Mucosal Immunol"},{"key":"R59-20240828","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1167\/iovs.09-3838","article-title":"Desiccating stress promotion of Th17 differentiation by ocular surface tissues through a dendritic cell-mediated pathway","volume":"51","author":"Zheng","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R60-20240828","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.sjbs.2018.08.009","article-title":"Role of diagnostic factors associated with antioxidative status and expression of matrix metalloproteinases [MMPs] in patients with cancer therapy induced ocular disorders","volume":"25","author":"Rasool","year":"2018","journal-title":"Saudi J Biol Sci"},{"key":"R61-20240828","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.bbmt.2016.07.012","article-title":"Novel scoring criteria for the evaluation of ocular graft-versus-host disease in a preclinical allogeneic hematopoietic stem cell transplantation animal model","volume":"22","author":"Perez","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R62-20240828","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1017\/S1431927617000538","article-title":"The conjunctiva-associated lymphoid tissue in chronic ocular surface diseases","volume":"23","author":"Mastropasqua","year":"2017","journal-title":"Microsc Microanal"},{"key":"R63-20240828","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.mehy.2017.06.012","article-title":"Hyperhomocysteinemia and age-related macular degeneration:Role of inflammatory mediators and pyroptosis;a proposal","volume":"105","author":"Singh","year":"2017","journal-title":"Med Hypotheses"},{"key":"R64-20240828","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jaut.2018.02.010","article-title":"Systemic activation of NLRP3 inflammasome in patients with severe primary Sj\u00f6gren's syndrome fueled by inflammagenic DNA accumulations","volume":"91","author":"Vakrakou","year":"2018","journal-title":"J Autoimmun"},{"key":"R65-20240828","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.2147\/JIR.S310116","article-title":"Calcitriol alleviates hyperosmotic stress-induced corneal epithelial cell damage via inhibiting the NLRP3-ASC-Caspase-1-GSDMD Pyroptosis pathway in dry eye disease","volume":"14","author":"Zhang","year":"2021","journal-title":"J Inflamm Res"},{"key":"R66-20240828","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.exer.2015.02.013","article-title":"Reactive oxygen species activated NLRP3 inflammasomes initiate inflammation in hyperosmolarity stressed human corneal epithelial cells and environment-induced dry eye patients","volume":"134","author":"Zheng","year":"2015","journal-title":"Exp Eye Res"},{"key":"R67-20240828","doi-asserted-by":"crossref","first-page":"108452","DOI":"10.1016\/j.exer.2021.108452","article-title":"Comparative influence of differentiation and proliferation on gene expression in human meibomian gland epithelial cells","volume":"205","author":"Yang","year":"2021","journal-title":"Exp Eye Res"},{"key":"R68-20240828","doi-asserted-by":"crossref","first-page":"18039","DOI":"10.1038\/s41598-017-13678-5","article-title":"Leukocyte-associated immunoglobulin-like receptor-1 is regulated in human myocardial infarction but its absence does not affect infarct size in mice","volume":"7","author":"Ellenbroek","year":"2017","journal-title":"Sci Rep"},{"key":"R69-20240828","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.ajpath.2019.04.015","article-title":"E-Cadherin is important for meibomian gland function as revealed by a new human ex vivo slice culture model","volume":"189","author":"R\u00f6tzer","year":"2019","journal-title":"Am J Pathol"},{"key":"R70-20240828","doi-asserted-by":"crossref","first-page":"7267","DOI":"10.1167\/iovs.11-7231","article-title":"Tear production and ocular surface changes in experimental dry eye after elimination of desiccating stress","volume":"52","author":"Yoon","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R71-20240828","doi-asserted-by":"crossref","first-page":"108284","DOI":"10.1016\/j.exer.2020.108284","article-title":"Corneal nerve abnormalities in ocular and systemic diseases","volume":"202","author":"Patel","year":"2021","journal-title":"Exp Eye Res"},{"key":"R72-20240828","first-page":"571","article-title":"Diagnosis and management of neurotrophic keratitis","volume":"8","author":"Sacchetti","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"R73-20240828","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0161-6420(00)00163-9","article-title":"Topical treatment with nerve growth factor for neurotrophic keratitis","volume":"107","author":"Bonini","year":"2000","journal-title":"Ophthalmology"},{"key":"R74-20240828","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.2147\/OPTH.S185184","article-title":"Update on cenegermin eye drops in the treatment of neurotrophic keratitis","volume":"13","author":"Sheha","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"R75-20240828","first-page":"71","article-title":"The pathophysiology, diagnosis, and treatment of dry eye disease","volume":"112","author":"Messmer","year":"2015","journal-title":"Dtsch Arztebl Int"},{"key":"R77-20240828","doi-asserted-by":"crossref","first-page":"e000697","DOI":"10.1136\/bmjophth-2020-000697","article-title":"Dry eye:Why artificial tears are not always the answer","volume":"6","author":"Kim","year":"2021","journal-title":"BMJ Open Ophthalmol"},{"key":"R78-20240828","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/ICU.0000000000000141","article-title":"Current treatments and preventive strategies for radiation retinopathy","volume":"26","author":"Reichstein","year":"2015","journal-title":"Curr Opin Ophthalmol"},{"key":"R79-20240828","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.clae.2009.06.006","article-title":"Rigid gas permeable contact lenses:Out in the cold","volume":"32","author":"Jackson","year":"2009","journal-title":"Cont Lens Anterior Eye"},{"key":"R80-20240828","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s10792-021-01692-6","article-title":"Efficacy of bandage contact lens for the management of dry eye disease after cataract surgery","volume":"41","author":"Wu","year":"2021","journal-title":"Int Ophthalmol"},{"key":"R81-20240828","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jtos.2021.04.011","article-title":"Clinical practice patterns in the management of dry eye disease:A TFOS international survey","volume":"21","author":"Wolffsohn","year":"2021","journal-title":"Ocul Surf"},{"key":"R82-20240828","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/ICU.0000000000000768","article-title":"Alternative therapies for dry eye disease","volume":"32","author":"Mittal","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"key":"R83-20240828","doi-asserted-by":"crossref","first-page":"DES169","DOI":"10.1167\/iovs.17-23576","article-title":"Regeneration of lacrimal gland function to maintain the health of the ocular surface","volume":"59","author":"Kawakita","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R84-20240828","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jtos.2015.10.004","article-title":"The matrix metalloproteinase 9 point-of-care test in dry eye","volume":"14","author":"Lanza","year":"2016","journal-title":"Ocul Surf"},{"key":"R85-20240828","first-page":"240","article-title":"Dry eye:An inflammatory ocular disease","volume":"9","author":"Hessen","year":"2014","journal-title":"J Ophthalmic Vis Res"},{"key":"R86-20240828","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1167\/iovs.13-13577","article-title":"Therapeutic effects of topical doxycycline in a benzalkonium chloride-induced mouse dry eye model","volume":"55","author":"Zhang","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R87-20240828","first-page":"1447","article-title":"Managing Sj\u00f6gren's syndrome and non-Sj\u00f6gren syndrome dry eye with anti-inflammatory therapy","volume":"8","author":"Coursey","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"R88-20240828","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/ICO.0000000000000309","article-title":"Topical NSAIDs effect on corneal sensitivity","volume":"34","author":"Singer","year":"2015","journal-title":"Cornea"},{"key":"R89-20240828","first-page":"e19","article-title":"Dry eye","volume":"379","author":"Maayan","year":"2018","journal-title":"N Engl J Med"},{"key":"R90-20240828","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1097\/ICO.0b013e31824988e5","article-title":"The effect of topical pranoprofen 0.1% on the clinical evaluation and conjunctival HLA-DR expression in dry eyes","volume":"31","author":"Liu","year":"2012","journal-title":"Cornea"},{"key":"R91-20240828","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000074074","article-title":"Effects of topical corticosteroids and nonsteroidal anti-inflammatory drugs on prostaglandine2-induced aqueous flare elevation in pigmented rabbits","volume":"35","author":"Hayasaka","year":"2003","journal-title":"Ophthalmic Res"},{"key":"R92-20240828","first-page":"112","article-title":"Efficacy of several therapeutic agents in a murine model of dry eye syndrome","volume":"66","author":"Kilic","year":"2016","journal-title":"Comp Med"},{"key":"R93-20240828","first-page":"741","article-title":"Corneal sensitivity after topical bromfenac sodium eye-drop instillation","volume":"7","author":"Yanai","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"R94-20240828","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ophtha.2013.07.006","article-title":"Bromfenac ophthalmic solution 0.07% dosed once daily for cataract surgery:Results of 2 randomized controlled trials","volume":"121","author":"Walters","year":"2014","journal-title":"Ophthalmology"},{"key":"R95-20240828","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II management and therapy report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul Surf"},{"key":"R96-20240828","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ophtha.2015.09.029","article-title":"Topical fluorometholone protects the ocular surface of dry eye patients from desiccating stress:A randomized controlled clinical trial","volume":"123","author":"Pinto-Fraga","year":"2016","journal-title":"Ophthalmology"},{"key":"R97-20240828","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1089\/jop.2020.0014","article-title":"Loteprednol etabonate for the treatment of dry eye disease","volume":"36","author":"Beckman","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"key":"R98-20240828","first-page":"75","article-title":"Loteprednol 0.25% [Eysuvis] for dry eye disease","volume":"63","year":"2021","journal-title":"Med Lett Drugs Ther"},{"key":"R99-20240828","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/ICO.0000000000002452","article-title":"Safety of KPI-121 ophthalmic suspension 0.25% in patients with dry eye disease: A Pooled analysis of 4 multicenter, randomized, vehicle-controlled studies","volume":"40","author":"Korenfeld","year":"2021","journal-title":"Cornea"},{"key":"R100-20240828","doi-asserted-by":"crossref","first-page":"8201053","DOI":"10.1155\/2016\/8201053","article-title":"Dry eye syndrome in patients with diabetes mellitus:Prevalence, etiology, and clinical characteristics","volume":"2016","author":"Zhang","year":"2016","journal-title":"J Ophthalmol"},{"key":"R101-20240828","doi-asserted-by":"crossref","first-page":"e9935","DOI":"10.1097\/MD.0000000000009935","article-title":"Evaluation of a new matrix regenerating agent in patients with Sj\u00f6gren syndrome and superficial ulcerative keratitis resistant to conventional therapy: A report of 3 cases","volume":"97","author":"Fajnkuchen","year":"2018","journal-title":"Medicine [Baltimore]"},{"key":"R102-20240828","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1167\/iovs.13-12925","article-title":"Effect of 0.025% FK-506 eyedrops on botulinum toxin B-induced mouse dry eye","volume":"56","author":"Lin","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R103-20240828","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.clae.2015.04.004","article-title":"Treatment of Sj\u00f6gren's syndrome dry eye using 0.03% tacrolimus eye drop:Prospective double-blind randomized study","volume":"38","author":"Moscovici","year":"2015","journal-title":"Cont Lens Anterior Eye"},{"key":"R104-20240828","doi-asserted-by":"crossref","first-page":"1604235","DOI":"10.3389\/ijph.2021.1604235","article-title":"Associations between air pollution exposure and daily pediatric outpatient visits for dry eye disease: A time-series study in Shenzhen, China","volume":"66","author":"Mu","year":"2021","journal-title":"Int J Public Health"},{"key":"R105-20240828","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/jop.2016.0105","article-title":"LFA-1\/ICAM-1 interaction as a therapeutic target in dry eye disease","volume":"33","author":"Pflugfelder","year":"2017","journal-title":"J Ocul Pharmacol Ther"},{"key":"R106-20240828","doi-asserted-by":"crossref","first-page":"49","DOI":"10.18433\/jpps29895","article-title":"Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease:Overview of clinical trial program","volume":"22","author":"Chan","year":"2019","journal-title":"J Pharm Pharm Sci"},{"key":"R107-20240828","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1358\/dot.2016.52.9.2542066","article-title":"Lifitegrast: First LFA-1\/ICAM-1 antagonist for treatment of dry eye disease","volume":"52","author":"Paton","year":"2016","journal-title":"Drugs Today [Barc]"},{"key":"R108-20240828","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2147\/OPTH.S296510","article-title":"Real-world experience with lifitegrast ophthalmic solution [Xiidra\u00ae] in the US and Canada:Retrospective study of patient characteristics, treatment patterns, and clinical effectiveness in 600 patients with dry eye disease","volume":"15","author":"Hovanesian","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"R109-20240828","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1749-6632.2012.06682.x","article-title":"Thymosin \u03b24:A potential novel dry eye therapy","volume":"1270","author":"Sosne","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"R110-20240828","first-page":"877","article-title":"Thymosin beta 4 ophthalmic solution for dry eye: A randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment [CAE\u2122] model","volume":"9","author":"Sosne","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"R111-20240828","doi-asserted-by":"crossref","first-page":"10500","DOI":"10.1038\/s41598-018-28861-5","article-title":"RGN-259 [thymosin \u00df4] improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model","volume":"8","author":"Kim","year":"2018","journal-title":"Sci Rep"},{"key":"R112-20240828","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/OPTH.S150433","article-title":"Comparison of a single-dose vectored thermal pulsation procedure with a 3-month course of daily oral doxycycline for moderate-to-severe meibomian gland dysfunction","volume":"12","author":"Hagen","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"R113-20240828","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.clae.2015.08.002","article-title":"On the prescribing of oral doxycycline or minocycline by UK optometrists as part of management of chronic Meibomian Gland Dysfunction (MGD)","volume":"39","author":"Doughty","year":"2016","journal-title":"Cont Lens Anterior Eye"},{"key":"R114-20240828","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ajo.2012.06.009","article-title":"Minocycline controls clinical outcomes and inflammatory cytokines in moderate and severe meibomian gland dysfunction","volume":"154","author":"Lee","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"R115-20240828","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/ICL.0b013e31823ff229","article-title":"Safety and efficacy of topical azithromycin ophthalmic solution 1.0% in the treatment of contact lens-related dry eye","volume":"38","author":"Nichols","year":"2012","journal-title":"Eye Contact Lens"},{"key":"R116-20240828","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/ICO.0b013e3181cda38f","article-title":"Topical azithromycin therapy for meibomian gland dysfunction:Clinical response and lipid alterations","volume":"29","author":"Foulks","year":"2010","journal-title":"Cornea"},{"key":"R117-20240828","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.3760\/cma.j.issn.0366-6999.20140048","article-title":"Clinical efficacy of 0.1% pranoprofen in treatment of dry eye patients:A multicenter, randomized, controlled clinical trial","volume":"127","author":"Chen","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"R118-20240828","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2147\/OPTH.S101836","article-title":"Comparison of effect of nepafenac and diclofenac ophthalmic solutions on cornea, tear film, and ocular surface after cataract surgery:The results of a randomized trial","volume":"10","author":"Kawahara","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"R119-20240828","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3349\/ymj.2014.55.1.203","article-title":"Inflammatory cytokine and osmolarity changes in the tears of dry eye patients treated with topical 1% methylprednisolone","volume":"55","author":"Lee","year":"2014","journal-title":"Yonsei Med J"},{"key":"R120-20240828","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3390\/pharmaceutics13060905","article-title":"Dexamethasone-loaded nanostructured lipid carriers for the treatment of dry eye disease","volume":"13","author":"Kumari","year":"2021","journal-title":"Pharmaceutics"},{"key":"R121-20240828","doi-asserted-by":"crossref","first-page":"e1082","DOI":"10.1111\/aos.14113","article-title":"Fluorometholone modulates gene expression of ocular surface mucins","volume":"97","author":"Taniguchi","year":"2019","journal-title":"Acta Ophthalmol"},{"key":"R122-20240828","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1358\/dot.2022.58.2.3367993","article-title":"Loteprednol etabonate:A formulation for short-term use in inflammatory flares in dry eye disease","volume":"58","author":"Paton","year":"2022","journal-title":"Drugs Today (Barc)"},{"key":"R123-20240828","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/ICL.0000000000000049","article-title":"Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%","volume":"40","author":"Sheppard","year":"2014","journal-title":"Eye Contact Lens"},{"key":"R124-20240828","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.2147\/OPTH.S259331","article-title":"Preclinical efficacy comparison of cyclosporine ophthalmic solution 0.09% vs cyclosporine ophthalmic emulsion 0.05% vs ciclosporin ophthalmic emulsion 0.1% in a nod mouse model of dry eye disease","volume":"14","author":"Burade","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"R125-20240828","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/1120672121992680","article-title":"Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to Sjogren syndrome","volume":"32","author":"Moawad","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"R126-20240828","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1089\/jop.2020.0005","article-title":"Calcineurin inhibitor voclosporin preserves corneal barrier and conjunctival goblet cells in experimental dry eye","volume":"36","author":"Alam","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"issue":"(Suppl 1)","key":"R127-20240828","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/ICL.0000000000000601","article-title":"Clinical outcomes of lifitegrast 5% ophthalmic solution in the treatment of dry eye disease","volume":"46","author":"Tong","year":"2020","journal-title":"Eye Contact Lens"},{"key":"R128-20240828","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ophtha.2013.09.015","article-title":"Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: Results of the OPUS-1 phase 3 study","volume":"121","author":"Sheppard","year":"2014","journal-title":"Ophthalmology"},{"key":"R129-20240828","first-page":"319","article-title":"Anti-inflammatory effects of glycine thymosin \u00df4 eye drops in experimental dry eye","volume":"12","author":"Jin","year":"2020","journal-title":"Biomed Rep"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_481_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:29:40Z","timestamp":1786724980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_481_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":128,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_481_23","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"2023-02-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}